New Draft FDA Guidance On ADC Pharmacology

The market for antibody-drug conjugates, or ADCs, is hotter than ever before. In response, the Food and Drug Administration (FDA) released new guidance on clinical pharmacology considerations for ADCs, EndPoints News reports. Read on to find out more about the new guidelines on ADC pharmacology, as well as what the guidelines mean for research organizations and drug companies.

What Are ADCs?

Antibody-drug conjugates, or ADCs, are highly targeted biopharmaceutical drugs that are primarily used to treat cancer. These drugs combine monoclonal antibodies with potent anti-cancer agents, which makes them extremely effective against certain types of tumor cells. Currently, 12 ADCs for various cancer targets have FDA approval, and several others are coming to market soon.